Esophageal Cancer Showing Complete Remission of Nephrotic Syndrome after Neoadjuvant Chemotherapy Plus Surgery

Chao Cheng, Weixiong Yang, Shuishen Zhang and Sai-Ching Jim Yeung

Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-sen University, China
Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, USA

^*Correspondance to: Chao Cheng 

 PDF  Full Text DOI: 10.25107/2474-1647.2359

Abstract

How to treat esophageal cancer with concurrent nephrotic syndrome is major challenge. We report a patient treated with neoadjuvant chemotherapy plus surgical resection of esophageal cancer, resulting in a complete remission of NS. The patient achieved partial response and down staged from cT2N1M0 to cT1bN0M0 after neoadjuvant chemotherapy (nedaplatin and liposomal paclitaxel). Using intravenous albumin to maintain serum albumin >30 g/L, esophagectomy via video-assisted Mckewon approach was performed with no major perioperative complications. There was no recurrence of cancer or relapse of NS at 32 months after surgery. We concluded that neoadjuvant chemotherapy plus esophagectomy with Mckewon approach seems to be safe and effective for esophageal cancer patient with NS, maintaining serum albumin >30 g/L may mitigate concerns of surgical complications.

Keywords

Esophageal cancer; Nephrotic syndrome; Neoadjuvant chemotherapy; Surgery

Cite the article

Cheng C, Yang W, Zhang S, Jim Yeung S-C. Esophageal Cancer Showing Complete Remission of Nephrotic Syndrome after Neoadjuvant Chemotherapy Plus Surgery. Clin Surg. 2019; 4: 2359.